Literature DB >> 17433376

Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice.

Stéphanie Weiss1, Eleni T Tzavara, Richard J Davis, George G Nomikos, J Michael McIntosh, Bruno Giros, Marie-Pascale Martres.   

Abstract

Mice lacking the dopamine (DA) transporter (DAT) gene exhibit a phenotype reminiscent of schizophrenia and attention deficit hyperactivity disorder (ADHD), including hyperDAergia, hyperactivity and deficits in cognitive performance, which are alleviated by antipsychotic agents. Numerous studies suggest a dysfunction of nicotinic neurotransmission in schizophrenia and show increased tobacco intake in schizophrenic and ADHD patients, possibly as a self-medication. Thus, we examined the potential alteration of nicotinic neurotransmission in DAT knock-out (KO) mice. We showed that constitutively hyperDAergic DAT KO mice exhibited modifications in nicotinic receptor density in an area- and subtype-dependent manner. In some DAergic areas, the small decrease in the beta2* nicotinic subunit (nAChR) density contrasted with the higher decrease and increase in the alpha6* and alpha7 nAChR densities, respectively. Mutant mice were hypersensitive to the stimulant locomotor effects of nicotine at low doses, probably due to enhanced nicotine-induced extracellular DA level. They also showed hypersensitivity to the hypolocomotion induced by nicotine. In contrast, no hypersensitivity was observed for other nicotine-induced behavioral effects, such as anxiety or motor activity in the elevated plus maze. Co-administration of nicotinic agonists at sub-active doses elicited opposite locomotor effects in wild-type and DAT KO mice, as reported previously for methylphenidate. Interestingly, such a co-administration of nicotinic agonists induced synergistic hypolocomotion in DAT KO mice. These findings show that a targeted increase of DA tone can be responsible for significant adaptations of the cholinergic/nicotinic neurotransmission. This study may provide potential leads for the use of nicotine or combined nicotinic agonists for the therapy of psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17433376     DOI: 10.1016/j.neuropharm.2007.02.002

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  18 in total

Review 1.  Negative affective states and cognitive impairments in nicotine dependence.

Authors:  F Scott Hall; Andre Der-Avakian; Thomas J Gould; Athina Markou; Mohammed Shoaib; Jared W Young
Journal:  Neurosci Biobehav Rev       Date:  2015-06-06       Impact factor: 8.989

2.  Constitutive plasma membrane monoamine transporter (PMAT, Slc29a4) deficiency subtly affects anxiety-like and coping behaviours.

Authors:  T Lee Gilman; Christina M George; Melissa Vitela; Myrna Herrera-Rosales; Mohamed S Basiouny; Wouter Koek; Lynette C Daws
Journal:  Eur J Neurosci       Date:  2018-05-24       Impact factor: 3.386

3.  Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine.

Authors:  Osamu Uchiumi; Yoshiyuki Kasahara; Asami Fukui; F Scott Hall; George R Uhl; Ichiro Sora
Journal:  Neuropharmacology       Date:  2012-07-15       Impact factor: 5.250

Review 4.  Exploring the Validity of Proposed Transgenic Animal Models of Attention-Deficit Hyperactivity Disorder (ADHD).

Authors:  June Bryan de la Peña; Irene Joy Dela Peña; Raly James Custodio; Chrislean Jun Botanas; Hee Jin Kim; Jae Hoon Cheong
Journal:  Mol Neurobiol       Date:  2017-05-22       Impact factor: 5.590

Review 5.  The neurobiological basis of ADHD.

Authors:  Paolo Curatolo; Elisa D'Agati; Romina Moavero
Journal:  Ital J Pediatr       Date:  2010-12-22       Impact factor: 2.638

6.  Association of tobacco and lead exposures with attention-deficit/hyperactivity disorder.

Authors:  Tanya E Froehlich; Bruce P Lanphear; Peggy Auinger; Richard Hornung; Jeffery N Epstein; Joe Braun; Robert S Kahn
Journal:  Pediatrics       Date:  2009-11-23       Impact factor: 7.124

7.  Evidence of long-term expression of behavioral sensitization to both cocaine and ethanol in dopamine transporter knockout mice.

Authors:  Elise Morice; Cécile Denis; Bruno Giros; Marika Nosten-Bertrand
Journal:  Psychopharmacology (Berl)       Date:  2009-11-24       Impact factor: 4.530

Review 8.  The genetic components of alcohol and nicotine co-addiction: from genes to behavior.

Authors:  Isabel R Schlaepfer; Nicole R Hoft; Marissa A Ehringer
Journal:  Curr Drug Abuse Rev       Date:  2008-06

9.  Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice.

Authors:  Susan B Powell; Jared W Young; Jacob C Ong; Marc G Caron; Mark A Geyer
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

10.  Proteomic analysis of an alpha7 nicotinic acetylcholine receptor interactome.

Authors:  Joao A Paulo; William J Brucker; Edward Hawrot
Journal:  J Proteome Res       Date:  2009-04       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.